Infectious diseases remain an extremely important problem of modern medicine. The COVID-19 pandemic has reminded us of the danger that viruses and microorganisms can pose to human life in a globalized world. We are once again convinced that the development of effective antiviral agents still remains an extremely difficult task. In addition, the high frequency of concomitant bacterial pneumonias has actualized the problem of the development of resistance to antibiotics, which WHO recognizes as one of the main threats to global health.
The problem of chemoresistance of microorganisms was and remains one of our priority challenges. We cooperate with research organizations in the search for new highly effective antibacterial and antimicrobial agents, investigate additional properties of known drugs in relation to infectious agents, search for combinations of molecules that can mutually potentiate the antimicrobial effect. Thus, in addition to monopreparations of antibiotics of various classes, YURiA-PHARM produces combined preparations designed to ensure high clinical effectiveness, including in cases of complex infections caused by various types of microorganisms.
Since the beginning of the COVID-19 pandemic, the YURiA-PHARM team, like the global medical community, has been looking for potential solutions to the problem. For this purpose, within the framework of international cooperation, research was conducted on the basis of the Pasteur Institute (Paris, France) and the Institute of Medical Virology (Frankfurt, Germany) of the anti-coronavirus activity of two potential products – Aminocaproic acid, which is a long-known agent with potential antiviral properties, and Decametoxin – an original antiseptic product with a wide spectrum of anti-infective action. Studies at both scientific institutions have shown significant anti-coronavirus activity of the investigated agents. Currently, further studies are planned to ensure the official use of the products in the treatment regimens for COVID-19.
Separately, in this direction, it is possible to single out a line of drugs for tuberculosis – a dangerous disease that requires special attention and treatment. In addition to finding substances that have a direct effect against a specific pathogen, we are actively working on increasing their effectiveness by adapting the ways of drug administration. Thus, we have developed solutions for targeted delivery of the active substance to the focus of infection, as well as solutions for intravenous infusion, which allows to increase the concentration of the agent in the blood and tissues, while maintaining its safety profile.